People: XenoPort, Inc. (XNPT.O)

XNPT.O on Nasdaq

18.92USD
9 Feb 2010
Price Change (% chg)

$-0.20 (-1.05%)
Prev Close
$18.92
Open
--
Day's High
$19.36
Day's Low
$18.81
Volume
201,690
Avg. Vol
289,869
52-wk High
$27.37
52-wk Low
$13.36

view people for:

Summary

Name Age Since Current Position
Barrett, Ronald 53 2001 Chief Executive Officer, Director
Rieflin, William 48 2004 President
Harris, William 50 2001 Chief Financial Officer, Senior Vice President - Finance
Cundy, Kenneth 49 2004 Senior Vice President - Preclinical Development
Gallop, Mark 46 2004 Senior Vice President - Research
Savello, David 63 2007 Senior Vice President - Development
Angotti, Vincent 41 2008 Senior Vice President, Chief Commercialization Officer
Stamler, David 48 2008 Senior Vice President, Chief Medical Officer
Freund, John 55 1999 Director
Hilleman, Jeryl 51 2005 Director
Nussbacher, Kenneth 56 2000 Director
Wierenga, Wendell 61 2001 Director
Berns, Paul 42 2005 Director
Friedman, Catherine 48 2007 Director
Lofberg, Per 61 2008 Director
Fenton, Dennis 49 2009 Director
» Insider Trading

Biographies

Name Description
Barrett, Ronald Ronald W. Barrett, Ph.D. has been Chief Executive Officer and Director of XenoPort, Inc. Mr. Barrett is one of the founders and has served as the company's chief executive officer since September 2001. He served as the company's chief scientific officer from 1999 to 2001. Dr. Barrett has been a director since August 1999. From 1989 to 1999, he held various positions at Affymax Research Institute, a company employing combinatorial chemistry and high-throughput target screening for drug discovery, the most recent of which was senior vice president of research. Glaxo Wellcome plc, a pharmaceutical company, acquired Affymax Research Institute in 1995. Glaxo Wellcome subsequently merged with SmithKline Beecham plc, a pharmaceutical company, in 2000 to form GlaxoSmithKline plc, a pharmaceutical company. Prior to Affymax Research Institute, Dr. Barrett was a molecular pharmacologist in the Neuroscience Group at Abbott Laboratories, a healthcare company, from 1986 to 1989. Dr. Barrett received a B.S. from Bucknell University and a Ph.D. in pharmacology from Rutgers University.
Rieflin, William William J. Rieflin has been President of XenoPort, Inc. since September 2004. From 1996 to 2004, he held various positions with Tularik Inc., a biotechnology company focused on the discovery and development of product candidates based on the regulation of gene expression, the most recent of which was executive vice president, administration, chief financial officer, general counsel and secretary. Amgen Inc., a biotechnology company, acquired Tularik in 2004. Mr. Rieflin received a B.S. from Cornell University, an M.B.A. from the University of Chicago Graduate School of Business and a J.D. from Stanford Law School.
Harris, William William G. Harris has been Chief Financial Officer, Senior Vice President, Finance of XenoPort, Inc. since November 2001. From 1996 to 2001, he held several positions with Coulter Pharmaceutical, Inc., a biotechnology company engaged in the development of novel therapies for the treatment of cancer and autoimmune diseases, the most recent of which was senior vice president and chief financial officer. Corixa Corp., a developer of immunotherapeutic products, acquired Coulter Pharmaceutical in 2000. Prior to Coulter Pharmaceutical, from 1990 to 1996, Mr. Harris held several positions at Gilead Sciences, the most recent of which was director of finance. Mr. Harris received a B.A. from the University of California, San Diego and an M.B.A. from Santa Clara University, Leavey School of Business and Administration.
Cundy, Kenneth Kenneth C. Cundy, Ph.D. has been Senior Vice President, Preclinical Development of XenoPort, Inc. since January 2004. He was previously Company's vice president of biopharmaceutics from 2000 to 2004. From 1992 to 2000, he was senior director of biopharmaceutics at Gilead Sciences, Inc., a biopharmaceutical company. Prior to Gilead Sciences, Dr. Cundy was principal research investigator at Sterling Drug, a pharmaceutical division of Eastman Kodak Company, an imaging and photographic equipment company, from 1988 to 1992. He received a B.S. from the University of Manchester and a Ph.D. in pharmaceutical sciences from the University of Kentucky.
Gallop, Mark Mark A. Gallop has been Senior Vice President, Research of XenoPort, Inc. since January 2004. Mr. Gallop is one of the founders. He was previously the company's vice president of chemistry since 1999. From 1990 to 1999, Dr. Gallop held several positions at Affymax Research Institute, the most recent of which was senior director of combinatorial chemistry. Dr. Gallop received a B.Sc. from the University of Auckland and a Ph.D. in inorganic chemistry from the University of Cambridge.
Savello, David David R. Savello, Ph.D. has been Senior Vice President, Development of XenoPort, Inc. since February 2007. He was previously responsible for the company's regulatory affairs, quality and project management from 2005 to 2007. From 1999 to 2005, Dr. Savello was executive vice president and chief scientific officer for the Pharmaceutical Technology and Services Sector of Cardinal Health, Inc., a pharmaceutical services company. Prior to joining Cardinal Health, from 1997 to 1999, he was senior vice president for drug development at Guilford Pharmaceuticals Inc., a biotechnology company. From 1985 to 1997, Dr. Savello held several positions at Glaxo and Glaxo Wellcome including both vice president of drug development and vice president of regulatory affairs and compliance. Prior to that, he held R&D management and executive management positions at Boehringer Ingelheim GmbH, a pharmaceutical company, and 3M Company, a pharmaceutical company. Dr. Savello received his B.S. degree from the Massachusetts College of Pharmacy and an M.S. and Ph.D. in pharmaceutics from the University of Maryland School of Pharmacy.
Angotti, Vincent Vincent J. Angotti is Senior Vice President, Chief Commercialization Officer of XenoPort Inc, since May 2008. From 2001 to 2008, he held several positions with Reliant Pharmaceuticals, Inc., a pharmaceutical company, the most recent of which was senior vice president of sales and marketing. GlaxoSmithKline acquired Reliant Pharmaceuticals in 2008. Prior to Reliant Pharmaceuticals, from 1991 to 2001, Mr. Angotti held several positions at Novartis Pharmaceuticals Corporation, a pharmaceutical company, most recently as executive director, field operations. Mr. Angotti received a B.S. from Cornell University and an M.B.A. from Columbia University.
Stamler, David David A. Stamler, M.D. has been Senior Vice President, Chief Medical Officer of XenoPort, Inc. since July 2008. From 2005 to 2008, Dr. Stamler was chief scientific officer and head of drug development for Prestwick Pharmaceuticals, Inc., a pharmaceutical company, where he led clinical and pre-clinical development activities for a portfolio of CNS compounds. Prior to Prestwick, from 1997 to 2005, Dr. Stamler held several positions with Fujisawa Pharmaceutical Company, a pharmaceutical company, the most recent of which was senior global project leader for CNS Diseases and vice president of research and development, Medical Sciences for Fujisawa’s U.S. subsidiary, Fujisawa Healthcare, Inc. From 1993 to 1997, Dr. Stamler held several positions with Abbott Laboratories, the most recent of which was director of clinical research, Pharmaceutical Products for the International Division. Dr. Stamler received B.A. and M.D. degrees from the University of Chicago.
Freund, John John G. Freund has been a Member of Board of Directors of XenoPort, Inc. since 1999. He has been a managing director of Skyline Ventures, a venture capital firm specializing in healthcare companies, since 1997. From 1995 to 1997, Dr. Freund was a managing director in the private equity group at Chancellor Capital Management, a private capital investment firm. AMVESCAP plc, an investment services company, acquired Chancellor Capital Management in 1998 and renamed the division INVESCO Private Capital. In 1995, he co-founded Intuitive Surgical, Inc., a medical device company. From 1988 to 1994, he held various positions at Acuson Corp., a maker of ultrasound equipment, most recently as executive vice president. Siemens Corp. acquired Acuson in 2000. Prior to Acuson, Dr. Freund was a general partner of Morgan Stanley Venture Partners, a venture capital management firm, from 1987 to 1988. From 1982 to 1988, Dr. Freund was at Morgan Stanley & Co., an investment banking company, where he was a co-founder of the Healthcare Group in the Corporate Finance Department. He received a B.A. from Harvard College, an M.D. from Harvard Medical School and an M.B.A. from Harvard Business School. Dr. Freund is a member of the boards of directors of The New Economy Fund and the SMALLCAP World Fund, both of which are U.S.-registered investment funds, Hansen Medical, Inc., a publicly-traded company specializing in medical robotics, MAKO Surgical Corp., a publicly-traded company that designs and sells an advanced robotic-arm solution, together with proprietary implants, for minimally invasive orthopedic knee procedures, and MAP Pharmaceuticals, Inc., a publicly-traded company developing inhalation-based pharmaceuticals.
Hilleman, Jeryl Jeryl L. Hilleman has been a Member of Board of Directors of XenoPort, Inc. since January 2005. She is chief financial officer of Amyris Biotechnologies, Inc. Prior to joining Amyris in January 2008, she was executive vice president and chief financial officer of Symyx Technologies, Inc. from 1997 to June 2007. Prior to joining Symyx, Ms. Hilleman served as vice president finance and chief financial officer of two public biotechnology companies, Geron Corporation and Cytel Corporation, which merged with Epimmune Inc. in 1999. Ms. Hilleman received an A.B. from Brown University and an M.B.A. from the Wharton Graduate School of Business.
Nussbacher, Kenneth Kenneth J. Nussbacher has been a Member of Board of Directors of XenoPort, Inc. since 2000. He has been an Affymetrix fellow since 2000. From 1995 to 2000, Mr. Nussbacher was executive vice president of Affymetrix, Inc., a biotechnology company, and, from 1995 to 1997, he was also chief financial officer of Affymetrix. Prior to joining Affymetrix, Mr. Nussbacher was executive vice president for business and legal affairs of Affymax Research Institute. He received a B.S. from Cooper Union and a J.D. from Duke University.
Wierenga, Wendell Wendell Wierenga, Ph.D. has been a Member of Board of Directors of XenoPort, Inc. since 2001. He is executive vice president of research and development at Ambit Biosciences, Inc., a biopharmaceutical company engaged in the discovery and development of small-molecule kinase inhibitors. Prior to joining Ambit in January 2007, Dr. Wierenga served as executive vice president of research and development at Neurocrine Biosciences, Inc., a biopharmaceutical company developing therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases, since September 2003. From 2000 to 2003, Dr. Wierenga was chief executive officer of Syrrx, Inc., a company focused on small-molecule drug compounds. Prior to joining Syrrx, from 1990 to 2000, he was senior vice president of worldwide pharmaceutical sciences, technologies and development at Parke-Davis, a division of Warner Lambert Co., a pharmaceutical company. Pfizer Inc, a research-based pharmaceutical company, acquired Warner Lambert in 2000. Prior to Parke-Davis, Dr. Wierenga worked at Upjohn Co., later Pharmacia & Upjohn, Inc., a pharmaceutical and biotechnology company, for 16 years in various positions, most recently as executive director of discovery research. Pfizer acquired Pharmacia & Upjohn, then named Pharmacia Corp., in 2002. Dr. Wierenga received a B.S. from Hope College and a Ph.D. in chemistry from Stanford University. Dr. Wierenga is a member of the board of directors of Onyx Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company.
Berns, Paul Paul L. Berns has been a Member of Board of Directors of XenoPort, Inc. since November 2005. In March 2006, he was appointed president, chief executive officer and a member of the board of directors of Allos Therapeutics, Inc. From 2002 to 2005, Mr. Berns was chief executive officer, president and a director of Bone Care International, Inc. (acquired by Genzyme Corporation in 2005). From 2001 to 2002, Mr. Berns served as vice president and general manager of the Immunology, Oncology and Pain Therapeutics business unit of Abbott Laboratories. He served as vice president, marketing of BASF Pharmaceuticals-Knoll from 2000 to 2001. From 1990 to 2000, Mr. Berns held various positions, including senior management roles, at Bristol-Myers Squibb Company. Mr. Berns received a B.S. from the University of Wisconsin.
Friedman, Catherine Catherine J. Friedman has been a member of Board of Directors of XenoPort, Inc. since September 2007. Ms. Friedman has been an independent financial consultant serving private and public companies in the life sciences industry since 2006. Prior to that, Ms. Friedman held numerous positions over a 23-year investment banking career with Morgan Stanley & Co., an investment banking company, including Managing Director from 1997 to 2006 and Head of West Coast Healthcare and Co-Head of the Biotechnology Practice from 1993 to 2006. Ms. Friedman received a B.A. from Harvard College and an M.B.A. from the University of Virginia Darden School of Business. Ms. Friedman is a member of the board of directors of EnteroMedics Inc., a publicly-traded medical device company focused on obesity management.
Lofberg, Per Per G. H. Lofberg has been a member of Board of Directors of XenoPort, Inc. since July 2008. He has been chairman and a managing director of Pharma Capital Ventures, an investment company, since July 2008. From 2000 to July 2008, Mr. Lofberg was president and chief executive officer of Merck Capital Ventures, LLC, a subsidiary of Merck & Co., Inc., a pharmaceutical company, which invested in companies with technology-based solutions for the pharmaceutical industry. From 1993 to 2000, Mr. Lofberg was chairman of Merck-Medco Managed Care, LLC, a wholly-owned subsidiary of Merck & Co., Inc., and a provider of prescription drug benefit management services. Mr. Lofberg joined Merck-Medco in 1988 as senior executive vice president, a member of the office of the president and a director. Before Merck-Medco, Mr. Lofberg was a partner at The Boston Consulting Group, Inc., a management consulting company, and oversaw the firm’s worldwide health care practice. Mr. Lofberg received an M.S. degree from the Graduate School of Industrial Administration at Carnegie Mellon University and an undergraduate degree from the Stockholm School of Economics in Sweden. Mr. Lofberg is a member of the board of directors of inVentiv Health, Inc., a publicly-traded company providing commercialization services to the global pharmaceutical and life sciences industries.
Fenton, Dennis Dr. Dennis M. Fenton, Ph.D., is Director of XenoPort, Inc. During his tenure at Amgen, Dr. Fenton held numerous positions including executive roles in process development, manufacturing, sales and marketing and research and development. Most recently, Dr. Fenton served as Executive Vice President, responsible for worldwide operations, manufacturing, process development and quality. Under Dr. Fenton's leadership, Amgen established manufacturing operations in California, Colorado, Puerto Rico and Rhode Island. Dr. Fenton has a Bachelor of Science in Biology from Manhattan College and a Ph.D. in Microbiology from Rutgers University. Dr. Fenton serves on the board of trustees of Rutgers University and the Keck Graduate Institute. He is also a member of the boards of directors of Amira Pharmaceuticals, Inc., KYTHERA Biopharmaceuticals, Inc. and CytomX Therapeutics, LLC.

Basic Compensation

Name Fiscal Year Total
Barrett, Ronald 1,971,250
Rieflin, William 1,302,180
Harris, William 767,265
Cundy, Kenneth 639,045
Gallop, Mark 444,230
Savello, David 1,049,180
Angotti, Vincent 990,499
Stamler, David --
Freund, John --
Hilleman, Jeryl --
Nussbacher, Kenneth --
Wierenga, Wendell --
Berns, Paul --
Friedman, Catherine --
Lofberg, Per --
Fenton, Dennis --
As Of 30 Dec 2008

Options Compensation

Name Options Value
Barrett, Ronald 316,663 3,909,951
Rieflin, William 18,887 367,163
Harris, William 58,332 848,066
Cundy, Kenneth 582,221 207,050
Gallop, Mark 485,000 298,750
Savello, David 6,830 332,894
Angotti, Vincent 0 0
Stamler, David 0 0
Freund, John 0 0
Hilleman, Jeryl 0 0
Nussbacher, Kenneth 0 0
Wierenga, Wendell 0 0
Berns, Paul 0 0
Friedman, Catherine 0 0
Lofberg, Per 0 0
Fenton, Dennis 0 0

Insider Trading

Name Shares Traded Price
GALLOP MARK A 500 $0.00
CUNDY KENNETH C 2 $18.80
CUNDY KENNETH C 100 $18.39
CUNDY KENNETH C 269 $18.50
CUNDY KENNETH C 200 $18.36
CUNDY KENNETH C 100 $18.46
CUNDY KENNETH C 100 $18.43
CUNDY KENNETH C 100 $18.72
CUNDY KENNETH C 200 $18.60
BARRETT RONALD W 538 $18.50
CUNDY KENNETH C 100 $18.52
HARRIS WILLIAM G 215 $18.50
SAVELLO DAVID R 215 $18.50
CUNDY KENNETH C 68 $18.81
CUNDY KENNETH C 625 $0.00
CUNDY KENNETH C 200 $18.49
CUNDY KENNETH C 100 $18.32
CUNDY KENNETH C 100 $18.58
CUNDY KENNETH C 2,000 $1.50
CUNDY KENNETH C 30 $18.79
GALLOP MARK A 215 $18.50
BARRETT RONALD W 1,250 $0.00
CUNDY KENNETH C 100 $18.30
CUNDY KENNETH C 100 $18.50
HARRIS WILLIAM G 500 $0.00
» Full list on Insider Trading
view people for: